Get Published | Subscribe | About | Write for Our Blog    

News RSS Bioethics News.


Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.

External Link - Source: The New York Times

Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy.

This entry was posted in Health Regulation & Law, Pharmaceuticals. Bookmark the permalink.